ENTASIS THERAPEUTICS HLDGS I's ticker is ETTX and the CUSIP is 293614103. A total of 30 filers reported holding ENTASIS THERAPEUTICS HLDGS I in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $99,000 | -38.5% | 52,797 | -28.3% | 0.00% | -100.0% |
| Q4 2021 | $161,000 | -29.7% | 73,597 | +7.3% | 0.00% | 0.0% |
| Q3 2021 | $229,000 | +23.1% | 68,597 | -1.3% | 0.00% | 0.0% |
| Q2 2021 | $186,000 | +22.4% | 69,487 | -2.0% | 0.00% | 0.0% |
| Q1 2021 | $152,000 | -1.9% | 70,930 | +13.2% | 0.00% | 0.0% |
| Q4 2020 | $155,000 | +44.9% | 62,663 | +20.0% | 0.00% | 0.0% |
| Q3 2020 | $107,000 | -34.0% | 52,238 | -4.8% | 0.00% | 0.0% |
| Q2 2020 | $162,000 | +19.1% | 54,898 | +6.5% | 0.00% | 0.0% |
| Q1 2020 | $136,000 | -43.1% | 51,555 | +7.1% | 0.00% | -50.0% |
| Q4 2019 | $239,000 | -14.3% | 48,155 | +2.8% | 0.00% | 0.0% |
| Q3 2019 | $279,000 | -3.8% | 46,861 | +4.3% | 0.00% | 0.0% |
| Q2 2019 | $290,000 | +0.3% | 44,917 | +5.0% | 0.00% | 0.0% |
| Q1 2019 | $289,000 | +71.0% | 42,792 | +3.2% | 0.00% | 0.0% |
| Q4 2018 | $169,000 | – | 41,469 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 1,349,953 | $8,046,000 | 2.52% |
| Novo Holdings A/S | 2,181,843 | $13,004,000 | 2.23% |
| Sofinnova Investments, Inc. | 1,180,178 | $7,034,000 | 0.64% |
| TPG Group Holdings (SBS) Advisors, Inc. | 2,041,496 | $12,168,000 | 0.09% |
| Eventide Asset Management | 392,513 | $2,288,000 | 0.08% |
| Blackstone Inc. | 1,623,405 | $9,675,000 | 0.06% |
| Granahan Investment Management | 141,012 | $840,000 | 0.05% |
| Janney Montgomery Scott LLC | 46,861 | $279,000 | 0.00% |
| BANK OF MONTREAL /CAN/ | 5,921 | $35,000 | 0.00% |
| BlackRock Inc. | 15,755 | $94,000 | 0.00% |